Endonovo Therapeutics Inc (OTCMKTS:ENDV) Is A Potential Near Term Runner

Endonovo Therapeutics Inc (OTCMKTS:ENDV) currently trades for $0.06 a share. That's a close to 35% discount on April highs. Against a backdrop of share price decline, this is a company that's moving towards a number of key catalysts, each of which could bring with them some real strength. At current prices, therefore, we could be looking at a nice opportunity to pick up an exposure to these catalysts at a discount.Here's what we're looking at.Endonovo is a preclinical biotechnology company that has developed a technology that it calls its Immunotronics platform. The platform uses electrical signaling to help regenerate healthy cells in various parts of the body. It's fully patented and could be a game changer in numerous indications in the healthcare space if Endonovo can get it to market. Right now, the company is conducting a range of preclinical investigations in an attempt to put together data that can underpin an investigational new drug (IND) application with the FDA. This IND, if approved, would allow for the company's advance into human clinical trials and subsequent movement along the traditional clinical development pathway.It is these preclinical studies that we are looking to as the major near-term catalysts, and one, in particular, that could hit press any day now.Back at the end of last year, Endonovo kicked off a preclinical investigation assessing the Immunotronics platform in a target indication of myocardial infarction (or heart attack, as it’s more commonly known). The idea is to treat patients with the technology after they have suffered a first heart attack, with the goal of strengthening their cardiac muscle tissue and – in turn – reducing their chances of a second heart attack or complete heart failure (which is a remarkably common outcome in this patient population). At the trial's initiation, the company reported that it expected to have data with shareholders by the end of the first quarter of this year. Fast forward a few months, and alongside a release detailing a fresh patent issue for the technology, management amended its target data release date to early second quarter 2017. The numbers haven't hit press yet and we expect them to hit any day now.Why is this such a big deal? The implications of these numbers go beyond the myocardial infarction indication. The best way to look at his trial is as a sort of proof of concept study. If the company can prove that its technology has a regenerative impact on heart muscle tissue cells, there's no real reason why it won't have a similar impact on cells in other regions of the body.Management just recently reported the initiation of two further preclinical studies, one in NASH and another in critical limb ischemia, and we see this as positive for the treatment's chances of good MI data.Why?Well, it's speculative, but why would a company kick off an expanded program if the proof of concept looked like it was failing? Chances are that management likes what it is seeing in the MI study and that it's getting a jump on some expanded indications ahead of putting out the numbers.We don't have a target release date for the just initiated studies, but we expect them to take no longer than six months, meaning we should get an indication as to success or failure before the end of the year. Just as with the pending MI data, then, these two studies represent near-term catalysts for the company.We noted in our previous coverage that there's a chance we might see a split as the company tries to line up a NASDAQ listing. If the near-term data release comes out as indicative of efficacy in its target indication, however, such a split might not be necessary. There's a capital raise risk rooted in the necessity to fund advance to the clinic, but again, if we see said advance, it should add value to such a degree that any dilution impact will negate.Bottom line: it's all about the data release. If management can show that its platform works, this one's going to run.We will be updating our subscribers as soon as we know more. For the latest updates on ENDV, sign up below!Disclosure: We have no position in ENDV and have not been compensated for this article.